Literature DB >> 33085756

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

Jorge J Castillo1,2, Edward N Libby3, Stephen M Ansell4, M Lia Palomba5, Kirsten Meid1, Catherine A Flynn1, Carly Leventoff1, Christopher B Hergott6, Tomasz Sewastianik6, Elizabeth A Morgan6, Ruben Carrasco6, Jonathan R Fromm7, Guang Yang1, Zachary Hunter1,2, Steven P Treon1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33085756      PMCID： PMC7594378          DOI： 10.1182/bloodadvances.2020003087

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

Review 1.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Authors:  Gregory P Kaufman; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke
Journal:  Blood       Date:  2017-06-14       Impact factor: 22.113

3.  Extended rituximab therapy in Waldenström's macroglobulinemia.

Authors:  S P Treon; C Emmanouilides; E Kimby; A Kelliher; F Preffer; A R Branagan; K C Anderson; S R Frankel
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

4.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

5.  Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.

Authors:  William G Morice; Dong Chen; Paul J Kurtin; Curtis A Hanson; Ellen D McPhail
Journal:  Mod Pathol       Date:  2009-03-13       Impact factor: 7.842

6.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Authors:  Roger G Owen; Robert A Kyle; Marvin J Stone; Andy C Rawstron; Veronique Leblond; Giampaolo Merlini; Ramon Garcia-Sanz; Enrique M Ocio; Enrica Morra; Pierre Morel; Kenneth C Anderson; Christopher J Patterson; Nikhil C Munshi; Alessandra Tedeschi; Douglas E Joshua; Efstathios Kastritis; Evangelos Terpos; Irene M Ghobrial; Xavier Leleu; Morie A Gertz; Stephen M Ansell; William G Morice; Eva Kimby; Steven P Treon
Journal:  Br J Haematol       Date:  2012-11-15       Impact factor: 6.998

7.  Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Authors:  Aneel Paulus; Alak Manna; Sharoon Akhtar; Shumail M Paulus; Mayank Sharma; Marie V Coignet; Liuyan Jiang; Vivek Roy; Thomas E Witzig; Stephen M Ansell; John Allan; Richard Furman; Sonikpreet Aulakh; Rami Manochakian; Sikander Ailawadhi; Asher A Chanan-Khan; Taimur Sher
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

Review 8.  Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.

Authors:  Christine Chen; C Tom Kouroukis; Darrell White; Michael Voralia; Edward Stadtmauer; A Keith Stewart; John J Wright; Jean Powers; Wendy Walsh; Elizabeth Eisenhauer
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

9.  Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Authors:  Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

10.  Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Authors:  Estefanía García-Guerrero; Ralph Götz; Sören Doose; Markus Sauer; Alfonso Rodríguez-Gil; Thomas Nerreter; K Martin Kortüm; José A Pérez-Simón; Hermann Einsele; Michael Hudecek; Sophia Danhof
Journal:  Leukemia       Date:  2020-04-29       Impact factor: 11.528
View more
  3 in total

1.  Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Leuk Res Rep       Date:  2022-05-06

Review 2.  Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Authors:  Saurabh Zanwar; Jithma P Abeykoon
Journal:  Ther Adv Hematol       Date:  2022-04-29

Review 3.  The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Authors:  Obada Ababneh; Hassan Abushukair; Aref Qarqash; Sebawe Syaj; Samer Al Hadidi
Journal:  Clin Hematol Int       Date:  2022-05-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.